Tempus AI, Inc. (NASDAQ:TEM) Shares Purchased by First Horizon Advisors Inc.

First Horizon Advisors Inc. boosted its stake in Tempus AI, Inc. (NASDAQ:TEM) by 207.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,641 shares of the company’s stock after acquiring an additional 1,108 shares during the period. First Horizon Advisors Inc.’s holdings in Tempus AI were worth $55,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after purchasing an additional 539 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth approximately $67,000. Vestor Capital LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth approximately $153,000. The Manufacturers Life Insurance Company boosted its stake in shares of Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after acquiring an additional 2,765 shares in the last quarter. Finally, Stifel Financial Corp purchased a new stake in shares of Tempus AI during the 3rd quarter worth approximately $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $55.30 on Friday. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock has a fifty day moving average price of $52.29 and a 200 day moving average price of $52.27.

Wall Street Analyst Weigh In

TEM has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered Tempus AI from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $50.00 to $55.00 in a research note on Tuesday. Needham & Company LLC upped their target price on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday. Wolfe Research initiated coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. TD Cowen reiterated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Bank of America upped their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.55.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the transaction, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at $10,431,543.15. This represents a 17.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,823,701 shares of company stock worth $320,906,059.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.